Blemaren, 80 pcs.

When dissolving fizzy tablets Blemaren® in water, potassium sodium hydrocitrate and carbon dioxide are formed. When taking the drug, the pH of the urine increases.

Thus, the drug dissolves and prevents the formation of uric acid stones.

In addition, it increases citrate excretion and decreases calcium excretion, improves solubility of calcium oxalate in the urine, inhibits crystal formation and, therefore, prevents the formation of calcium-oxalate stones.

Bioavailability – about 100%. After a day of taking the preparation Blemaren® the administered amount of sodium and potassium is excreted from the body through the kidneys during 24-48 hours.

During long-term use of the drug daily excretion of potassium and sodium corresponds to the daily intake. In blood or plasma no significant changes in blood gases or electrolytes are noted.

This means that due to renal regulation of alkalinization acid-alkaline balance in the body is maintained, and accumulation of sodium and potassium with normal renal function does not occur.

Indications

Active ingredient

Composition

How to take, the dosage

Interaction

Simultaneous administration of drugs containing citrates and aluminum may lead to increased aluminum absorption. The interval between intakes of such drugs should be at least 2 hours.

The effect of cardiac glycosides may be impaired if simultaneously administered with the drug Blemaren® due to the presence of potassium in the drug.

Some drugs that lower blood pressure (aldosterone antagonists, potassium-saving diuretics, angiotensin-converting enzyme blockers, sartans) and anti-inflammatory non-steroidal drugs and analgesics may decrease potassium excretion.

Special Instructions

The average daily dose (4 effervescent tablets) contains about 1.5 mg of potassium and 0.9 g of sodium (to be considered in patients with limited intake of table salt).

It can be used in chronic renal failure that is not accompanied by retention of potassium ions.

Patients with diabetes can be prescribed.

In the dissolution of uric acid stones, excessive alkalinization of the urine should not be allowed for several days, because if the pH is increased above 7.8, phosphate precipitate may appear on the surface of the uric acid crystals, which may prevent further dissolution.

At the time of treatment, the intake of foods rich in proteins and purine bases should be limited, and sufficient fluid intake (at least 1.5-2 liters) should be provided.

Synopsis

Contraindications

Side effects

Overdose

In normal renal function, undesirable effects of the drug on changes in physiological metabolic parameters have not been noted, neither at the usual recommended dose nor at a higher dose, because excretion of excessive alkalis by the kidneys is a natural mechanism for regulating the acid-base balance in the body.

The upper limit of the urine pH range specified above should not be exceeded for several days, because there is an increased risk of crystallization of phosphate due to elevated pH (pH > 7.8).

Possible overdose can be corrected by reducing the dose of the drug. If necessary, measures can be taken to treat metabolic alkalosis.

Pregnancy use

There are no confirmed data on the undesirable effect of the drug Blemarin® during pregnancy and breastfeeding. Administration of the drug is possible after consultation with a physician.